公开(公告)号：EP2597093A4

公开(公告)日：2013-12-04

申请号：EP11809488

申请日：2011-05-17

Applicant: FUSO PHARMACEUTICAL IND

Inventor： OHISHI YOSHITAKA ,  TODA TAKAO ,  TAKEDA SEIICHI

IPC: C07D417/04 ,  A61K31/427 ,  A61P35/00

CPC classification number: C07D417/04

Abstract: Provided is a novel compound having an effective anti-cancer activity. The novel compound according to the present invention includes a compound represented by formula (I): [wherein R 1 represents an alkoxyalkyl group having 2 to 6 carbon atoms] or a pharmaceutically acceptable salt thereof.

公开(公告)号：JP2001240607A

公开(公告)日：2001-09-04

申请号：JP2000053475

申请日：2000-02-29

Applicant: FUSO PHARMACEUTICAL IND

Inventor： ARAKI HIROMASA ,  KAWAI KENZO ,  TANAKA SHUICHI ,  NISHIMURA KOUYO ,  OTANI HIRONARI ,  NISHIKAWA HIROYUKI ,  TAKEDA SEIICHI ,  SHIMADA CHIAKI ,  KITAGAWA CHIZUKO ,  ABE TOMOYUKI

IPC: A61K31/727 ,  A61P7/02 ,  A61P13/12 ,  A61P39/06 ,  C08B37/10

Abstract: PROBLEM TO BE SOLVED: To provide a method for depolymerizing a heparin, to obtain a new depolymerized heparin prepared by the method for depolymerization and its amidated derivative and further a pharmaceutical composition comprising the depolymerized heparin and its amidated derivative as active ingredients. SOLUTION: This method for depolymerizing the heparin is characterized by using a reducing metal and a metal oxide and the method for depolymerizing the heparin comprises the step. The depolymerized heparin is obtained by the method for depolymerization. Furthermore, the amidated depolymerized heparin is obtained and an anticoagulant, a therapeutic agent for renal diseases, a platelet aggregation inhibitor, a radical scavenger, a mesangium cell proliferation inhibitor and a complement activity inhibitor comprise the depolymerized heparin or the amidated depolymerized heparin derivative.

公开(公告)号：JPH09286803A

公开(公告)日：1997-11-04

申请号：JP3015097

申请日：1997-02-14

Applicant: FUSO PHARMACEUTICAL IND

Inventor： ARAKI HIROMASA ,  NISHIKAWA HIROYUKI ,  TANAKA SHUICHI ,  NAKAMURA KAZUMOTO ,  OTANI HIRONARI ,  NISHIMURA YUKIHIRO ,  SHIMADA CHIAKI ,  TAKEDA SEIICHI ,  KAWAI KENZO ,  KITAGAWA CHIZUKO ,  KUWABARA MASAAKI ,  ABE TOMOYUKI

IPC: C08B37/10 ,  A61K31/715 ,  A61P7/02 ,  A61P9/08 ,  A61P9/10 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  A61P37/08 ,  A61K31/725

Abstract: PROBLEM TO BE SOLVED: To obtain medium-molecular heparin which gives an amino acid deriv. effectively usable for various diseases reduced in bleeding tendency by depolymerizing heparin to a specified average mol.wt. SOLUTION: This medium-molecular heparin has an average mol.wt. of 8,500-9,500 and, when converted into an amino acid deriv., gives a medium- molecular heparinylamino acid deriv., more specifically a medium-molecular heparinylamino acid or its lower alkyl ester. The deriv. is used as the active component for compsns. for coagulation inhibition, nephric mesangial cell proliferation inhibition, cancer metastasis inhibition, complement activation inhibition, pulmonary inhibition, nephric disease inhibition, radical scavenging, allergic disease prevention, and a remedial medicine.